Prevalence and determinants of congenital cytomegalovirus infection at a rural South African central hospital in the Eastern Cape by Tshabalala, Donald et al.
Southern African Journal of Infectious Diseases is co-published by NISC (Pty) Ltd, Medpharm Publications, and Informa UK Limited  
(trading as the Taylor & Francis Group)
South Afr J Infect Dis
ISSN 2312-0053   EISSN 2313-1810
© 2018 The Author(s)
RESEARCH
Southern African Journal of Infectious Diseases 2018; 33(4):89–92
https://doi.org/10.1080/23120053.2018.1462560
Open Access article distributed under the terms of the
Creative Commons License [CC BY-NC 3.0]
http://creativecommons.org/licenses/by-nc/3.0
Prevalence and determinants of congenital cytomegalovirus infection at a rural 
South African central hospital in the Eastern Cape
Donald Tshabalalaa, Howard Newmanb*, Charles Busingec, Sikhumbuzo A Mabundad  , Waldette Kempe and Pakama Bejaa
a Department of Paediatrics, Nelson Mandela Academic Hospital and Walter Sisulu University, Mthatha, South Africa
b National Health Laboratory Service, Port Elizabeth, South Africa and Department of Pathology, Division of Medical Virology, Stellenbosch 
University, Cape Town, South Africa
c Department of Obstetrics and Gynaecology, Nelson Mandela Academic Hospital and Walter Sisulu University, Mthatha, South Africa
d Department of Public Health, Walter Sisulu University, Mthatha, South Africa
e National Health Laboratory Service, Port Elizabeth,  South Africa
*Corresponding author, email: howard.newman@nhls.ac.za  
Background: The Nelson Mandela Academic Hospital (NMAH) in Mthatha, Eastern Cape, is a rural central hospital, serving one of 
the poorest districts in South Africa. The prevalence of and risk factors for congenital cytomegalovirus (CMV) in this area are not 
known. The aim was to evaluate the prevalence of congenital CMV and associated risk factors for babies born at NMAH.
Methods: This was a cross-sectional study to determine the prevalence of congenital CMV infection among babies born at 
Nelson Mandela Academic Hospital. Mother–baby pairs delivered consecutively from Monday to Friday, who gave informed 
consent, were included. Demographic information was collected on a questionnaire. All babies were tested for congenital CMV 
using a saliva swab PCR within the first week of life.
Results: A total of 302 births were assessed. Congenital CMV was prevalent in 18 births (5.96%; 95% CI 3.29–8.63) and had an 
equal prevalence between HIV-exposed and HIV-unexposed newborns (prevalence ratio [PR] = 1.00; 95% CI 0.94–1.06; p = 0.869).
Conclusions: The prevalence of congenital CMV of 5.96% is similar to findings from other resource-limited settings. There was no 
significant association between maternal HIV status and congenital CMV. With the prevalence of congenital CMV being as high as 
it is in the studied setting, clinicians are advised to have a high index of suspicion, especially when mothers are CMV seropositive.
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Introduction
Human cytomegalovirus (CMV) is an enveloped double-stranded 
DNA virus belonging to the Herpesviridae family of viruses. CMV 
is distributed worldwide and affects humans of all ages and 
socio-economic backgrounds,1 with congenital CMV being a 
leading cause of congenital infections worldwide. In resource-
limited settings with very high CMV seroimmunity, congenital 
CMV rates of 1%–5% have been reported compared with rates of 
under 1% in industrialised nations.2
Maternal CMV infection during pregnancy most often results 
from close contact with young children.3 The risk of vertical 
transmission to the foetus is far higher with primary maternal 
infection than with recurrent infection (approximately 30% 
versus 1.5%).4 Advanced gestation and younger primigravid 
women appear to be factors linked to increased risk of 
transmission to the foetus.4, 5
Infants infected as a consequence of primary maternal infection 
are more likely to have symptoms at birth and suffer long-term 
sequelae than those infected as a result of maternal recurrent 
CMV infection. The risk of hearing loss, however, appears to be 
similar in both groups.6−8
Approximately 90% of neonates with congenital CMV infection 
will be asymptomatic at birth, with the remaining 10% having 
clinically apparent or symptomatic infection, where the disease 
manifestations can range from mild non-specific findings to 
multiple organ system involvement. The most commonly 
observed physical findings are petechial rash, jaundice and 
hepatosplenomegaly with neurological abnormalities such as 
microcephaly and lethargy.9 Neonates who are asymptomatic at 
birth have a 10% chance of developing sensorineural hearing 
loss later in life.9
The diagnosis of congenital CMV relies on virus detection by 
culture-based methods or PCR on saliva or urine specimens, 
collected within the first two  weeks of life.10 After this time 
period, virological testing cannot discriminate between 
intrauterine infection and postnatal infection.
An increased frequency of in utero CMV transmission in HIV-
infected mothers has been consistently documented in Western 
countries.2 HIV-infected newborns are also more likely to acquire 
congenital CMV than HIV-uninfected neonates.11 In the era of 
combination antiretroviral therapy (cART), the incidence of 
vertical transmission of CMV in HIV-positive mothers is falling 
and is associated with improvements in CD4 count.11 Some 
studies, however, have found no significant decrease in the 
prevalence of congenital CMV infection in children of HIV-
infected mothers receiving prenatal antiretroviral therapy.12
The Nelson Mandela Academic Hospital (NMAH) in Mthatha, 
Eastern Cape, is a rural central hospital, serving one of the 
poorest districts in South Africa. In addition, the prevalence of 
HIV in antenatal attendees within the area was estimated to be 
29% in 2012.13 Although there is a paucity of data regarding the 
prevalence of congenital CMV in this region, the prevalence is 
expected to be high due to poor socio-economic conditions and 
the high prevalence of HIV. We therefore undertook this study to 
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determine the prevalence and demographic determinants of 
congenital CMV in babies born at NMAH.
Materials and methods
A cross-sectional study to determine the prevalence of congenital 
CMV infection among babies born at Nelson Mandela Academic 
Hospital was conducted from January 2016, employing 
consecutive sampling. Nelson Mandela Academic Hospital is a 
512-bed rural central hospital, catering for one of the poorest 
districts in South Africa. Approximately 4 500 babies are delivered 
at NMAH annually, with a Caesarean section rate of approximately 
75%.
Mother–baby pairs delivered consecutively from Monday to 
Friday, who gave informed consent, were included. All those who 
declined to participate were excluded, as were mother–baby 
pairs where the HIV exposure status was unknown.
Sample size was calculated using the formula: n = Z2 α P(100-P)/e2. 
Assuming a precision (e) of 2.5%, and an alpha α = 0.05, the 
sample size required was 302.14,15 Maternal characteristics 
collected included maternal age, maternal parity, mode of 
delivery, maternal rapid plasma reagin (RPR) and maternal HIV 
status. The neonatal demographics included chronological age at 
testing, gender, gestational age at birth, birth weight, length at 
birth and head circumference at birth. The head circumference 
was measured within 48 hours of birth. The gestational age (in 
completed weeks) was determined either by obstetric estimation 
or by paediatric newborn examination. Neonates were classified 
as small for gestational age (less than the 10th percentile) or 
adequate for gestational age (the 10th percentile or greater) 
according to a standard reference curve.
Saliva swabs were collected for CMV polymerase chain reaction 
(PCR). The saliva samples were placed in phosphate buffered 
saline (PBS) and stored at –80 °C and sent to the NHLS pathology 
laboratory in Port Elizabeth for analysis. Cytomegalovirus PCR 
was performed on the COBAS® AmpliPrep/COBAS® Taqman® 
CMV Test (Roche, Basel, Switzerland), which was previously 
validated in-house for use with saliva samples. A positive result 
confirmed the diagnosis of congenital CMV.
All data collected were captured and coded in Microsoft Excel® 
2010 (Microsoft Corp, Redmond, WA, USA) and exported for 
analysis onto STATA® 14.1 (Stata Corp LP, College Station, TX, 
USA). Binomial logistic regression for estimation of risk/
prevalence ratio was used to determine the predictors of 
congenital CMV. Only bivariate associations are presented since 
model building did not yield a model that is better than the 
constant.
Results
A total of 307 mothers were approached to be included in the 
study. Three were excluded due to unknown maternal HIV status 
at the time of delivery, while two mothers did not provide 
informed consent and were thus excluded. A total of 302 births 
were assessed (Table 1). Almost two-thirds of births (64.24%; 
95% CI 58.64–69.47) were between 2 400 and 3 500 g at birth. 
Some 50% of the mothers were at least 26  years old and only 
25% of the mothers gave birth after the age of 32 years. Over a 
third of the babies were HIV exposed as 105 mothers (34.77%; 
95% CI 29.58–40.35) were HIV positive at delivery. All the HIV-
exposed newborns had a negative PCR when they were tested 
within three days of birth.
Table 1: Demographic characteristics
Variable Category n (%; 95% confidence interval) p-value
Sex Male 146 (48.34; 42.71–53.98) 0.416
Female 156 (51.66; 46.02–57.29)
Total 302 (100)
Birth weight (g) ≤ 2 400 74 (24.50; 19.96–29.70) 1
2 400–3 500 197 (65.23; 59.65–70.42) < 0.0001
≥ 3 500 31 (10.26; 7.30–14.25) < 0.0001
Mother’s HIV status Positive 105 (34.77; 29.58–40.35) 1
Negative 194 (64.24; 58.64–69.47) < 0.0001
Settlement Peri-urban 12 (3.97; 2.26–6.89) 1
Rural 268 (88.74; 84.63–91.86) < 0.0001
Urban 10 (3.31; 1.78–6.06) 0.664
Farm 12 (3.97; 2.26–6.89) 1
Category Interquartile range Median p-value
Birth weight (g) by Sex Male 2 380–3 216 2 850 0.928
Female 2 470–3 247.5 2 810
Total 2 440–3 240 2 840
Length Male 46–50 49 0.467
Female 47–50 49
Total 46–50 49
Head circumference Male 33–36 34 0.249
Female 32–35 34
Total 33–35 34
Mother’s age (years) Age 20–32 26 -
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Congenital CMV was prevalent in 18 births (5.96%; 95% CI 3.29–
8.63) and had an equal prevalence between HIV-exposed and 
HIV-unexposed newborns (prevalence ratio [PR] = 1.00; 95% CI 
0.94–1.06; p = 0.869). Children with a birth weight of 2 400 g or 
less were either 5% or 7% more likely to have congenital CMV 
than those with birth weights of between 2 400 and 3 500 g (PR 
= 1.05; 95% CI 0.97–1.14; p = 0.249) and 3 500 g or more (PR = 
1.07; 95% CI 0.97–1.18; p = 0.182) respectively. These prevalence 
ratios (Table 2), however, were not statistically significant. First-
born babies had a 5%, 2% and 6% higher risk of being born with 
congenital CMV than babies born to mothers with parities of 2, 3 
and 4 or more respectively. Congenital CMV infection was not 
significantly associated with the economic status or other 
maternal demographic characteristics (Table 2).
Discussion
This was the first study seeking to estimate the prevalence of 
congenital CMV at NMAH in Mthatha in the Eastern Cape 
province of South Africa. To date most prevalence studies on 
congenital CMV are from resource-rich countries whereas there 
is a paucity of data in resource-limited countries like South Africa. 
In 2014, Manicklal et al. evaluated the prevalence of congenital 
CMV in HIV-exposed infants in the Western Cape, South Africa, 
and found the prevalence of congenital CMV amongst this 
cohort to be 2.9%. They showed that type and length of ARV 
prophylaxis was not significantly different between CMV infected 
and uninfected infants. Studies of congenital CMV from other 
resource-limited settings show a prevalence ranging from 1% to 
5%,2,14,16 while the prevalence ranges from 0.6% to 0.7% in 
resource-rich countries, where maternal seroimmunity is lower.2 
In addition, HIV-infected newborns are more likely to acquire 
congenital CMV than HIV-uninfected neonates,11 whilst there 
have been conflicting reports on whether or not the incidence of 
vertical transmission of CMV in HIV-positive mothers is falling in 
the ARV era.11,12 The main finding of this study is a prevalence of 
congenital CMV of 5.96% (95% CI 3.29–8.63) among study 
participants, which is similar to findings from other resource-
limited settings.14,16 There was no significant association between 
maternal HIV status and congenital CMV, as the prevalence of the 
latter was equal in HIV-exposed versus HIV-unexposed neonates. 
Previous studies have shown that a maternal CD4 count < 200 
cells/μL during pregnancy was independently associated with 
congenital CMV.2 Evaluation of CD4 count was beyond the scope 
of this study, but it is possible that with the extensive roll-out of 
cART in South Africa, where all pregnant women qualify for HIV 
treatment irrespective of CD4 count, the majority of participants 
were well controlled on treatment, thus explaining the lack of a 
significant association between maternal HIV status and 
congenital CMV. In addition, none of the demographic 
characteristics listed in Table 2 were significantly associated with 
congenital CMV.
One of the limitations of this study was the relatively small but 
acceptable sample size,15 which could have affected the final 
prevalence result. In addition, it was beyond the scope of this 
study to evaluate the prevalence of symptomatic versus 
asymptomatic congenital CMV, as this would require not only 
physical examination of the newborns looking for the classical 
symptoms of congenital infections such as petechiae, 
hepatosplenomegaly and microcephaly, amongst others, but 
also clinical pathology testing to ascertain abnormalities such as 
thrombocytopenia and hyperbilirubinemia, as well as imaging 
such as head ultrasonography to screen for intracranial 
calcifications, for which resources were not available. This would 
be important to elucidate in future studies, as it has a direct 
impact on the health system, and may provide information that 
could affect how clinicians handle cases or suspected cases of 
congenital CMV, especially with regard to screening or diagnosis.
In conclusion, this study provides important data regarding the 
prevalence of congenital CMV in our setting and forms the basis 
for future studies on this potentially severe disease. With the 
prevalence of congenital CMV being as high as it is, clinicians are 
advised to have a high index of suspicion, especially when 
mothers are CMV seropositive.
Disclosure statement – No potential conflict of interest was 
reported by the authors.
Ethical clearance – Ethical clearance was obtained from the 
Human Research Ethics Committee of Walter Sisulu University 
(protocol number 029/2017).
Acknowledgements – The authors would like to thank the 
management of Nelson Mandela Academic Hospital who gave 
them all the necessary support. They would also like to thank the 
National Health Laboratory Service for the use of their facilities 
and resources. The authors thank the NHLS Research Trust for 
granting them funding to perform the laboratory testing. Most 
of all, the study would not have been possible without the 
support of patients who provided consent to participate in the 
study without any complaints or expectation of rewards. The 
authors thank you.
Funding – This work was supported by the NHLS Research Trust 
(grant number GRANT004_ 94534).
ORCID
Sikhumbuzo A Mabunda    http://orcid.org/0000-0001-9458-
3742
References
1.  Nelson CT, Demmler GJ. Cytomegalovirus infection in the pregnant 
mother, fetus, and newborn infant. Clin Perinatol. 1997;24(1): 151–60.
2.  Manicklal S, van Niekerk AM, Kroon SM, et al. Birth prevalence of 
congenital cytomegalovirus among infants of HIV-infected women 
on prenatal antiretroviral prophylaxis in South Africa. Clin Infect Dis. 
Table 2: Demographic predictors of congenital CMV at NMAH
Variable Category PR (95% confidence 
interval)
p-value
Baby’s sex Male 1 1
Female 1.00 (0.95–1.06) 0.885
Birth weight (g) ≤ 2 400 1 1
2 400–3 500 1.05 (0.97–1.14) 0.249
≥3 500 1.07 (0.97–1.18) 0.182
Mother’s age (years) ≤ 19 1 1
20–32 1.06 (0.96–1.16) 0.237
33–46 1.07 (0.96–1.18) 0.215
Mother’s parity 1 1 1
2 1.05 (0.97–1.14) 0.206
3 1.02 (0.94–1.11) 0.626
≥ 4 1.06 (0.99 (1.14) 0.084
Mother’s HIV status Positive 1 1
Negative 1.00 (0.94–1.06) 0.869
92 Southern African Journal of Infectious Diseases 2018; 33(4):89–92
Rev. 2013;26(1): 86–102. doi:10.1128/CMR.00062-12.
11.  Guibert G, Warszawski J, Le Chenadec J, et al. Decreased 
risk of congenital cytomegalovirus infection in children 
born to HIV-1-infected mothers in the era of highly active 
antiretroviral therapy. Clin Infect Dis. 2009(11);48: 1516–25. 
https://doi.org/10.1086/598934
12.  Frederick T, Homans J, Spencer L, et al. The effect of prenatal highly 
active antiretroviral therapy on the transmission of congenital and 
perinatal/early postnatal cytomegalovirus among HIV-infected 
and HIV-exposed infants. Clin Infect Dis. 2012;55(6): 877–84. 
doi:10.1093/cid/cis535. Epub 2012 Jun 6.
13.  Shisana O, Rehle T, Simbayi LC, et al. South African National HIV 
Prevalence, Incidence and Behaviour Survey, 2012. Cape Town: HSRC 
Press; 2014.
14.  van der Sande MA, Kaye S, Miles DJ, et al. Risk factors for and 
clinical outcome of congenital cytomegalovirus infection in a 
peri-urban West-African birth cohort. PLoS One 2007;2(6): e492. 
https://doi.org/10.1371/journal.pone.0000492
15.  Naing L, Winn T, Rusli BN. Practical Issues in Calculating the Sample 
Size for Prevalence Studies. Archives of Orofacial Sciences. 2006;1: 
9–14.
16.  Dar L, Pati SK, Patro AR, et al. Congenital cytomegalovirus 
infection in a highly seropositive semi-urban population 
in India. Pediatr Infect Dis J. 2008;27(9): 841–3. 
https://doi.org/10.1097/INF.0b013e3181723d55
Received: 21-09-2017 Accepted: 05-04-2018
2014;58(10): 1467–72. doi:10.1093/cid/ciu096. Epub 2014 Feb 23.
3.  Pass RF, Hutto C, Ricks R, Cloud GA. Increased rate of 
cytomegalovirus infection among parents of children attending 
day-care centers. N Engl J Med. 1986;314(22): 1414–18. 
https://doi.org/10.1056/NEJM198605293142204
4.  Kenneson A, Cannon MJ. Review and meta-analysis 
of the epidemiology of congenital cytomegalovirus 
(CMV) infection. Rev Med Virol. 2007;17(4): 253–76. 
https://doi.org/10.1002/(ISSN)1099-1654
5.  Picone O, Vauloup-Fellous C, Cordier AG, et al. A series of 
238 cytomegalovirus primary infections during pregnancy: 
description and outcome. Prenat Diagn. 2013;33(8): 751–8. 
doi:10.1002/pd.4118. Epub 2013 May 1.
6.  Goderis J, De Leenheer E, Smets K, et al. Hearing loss and congenital 
CMV infection: a systematic review. Pediatrics. 2014;134(5): 972–82. 
doi:10.1542/peds.2014-1173.
7.  Williamson WD, Demmler GJ, Percy AK, Catlin FI. Progressive hearing 
loss in infants with asymptomatic congenital cytomegalovirus 
infection. Pediatrics. 1992;90: 862–866.
8.  Fowler KB, McCollister FP, Dahle AJ, Boppana S, Britt 
WJ, Pass RF. Progressive and fluctuating sensorineural 
hearing loss in children with asymptomatic congenital 
cytomegalovirus infection. J Pediatr. 1997(4);130: 624–30. 
https://doi.org/10.1016/S0022-3476(97)70248-8
9.  Boppana SB, Ross SA, Fowler KB. Congenital cytomegalovirus 
infection: clinical outcome. Clin Infect Dis. 2013;57(Suppl 4): S178–
S181. doi:10.1093/cid/cit629.
10.  Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The 
“silent” global burden of congenital cytomegalovirus. Clin Microbiol 
